Revitalizing portfolio decision-making at Merck Serono S.A. - Geneva.
- Published in:
- Journal of Commercial Biotechnology, 2011, v. 17, n. 1, p. 24, doi. 10.1057/jcb.2010.26
- By:
- Publication type:
- Article
Works matching DE "MERCK Serono SA"
Results: 22
1
2
DRUG ALERTS.
- Published in:
- Australian Journal of Pharmacy, 2011, v. 92, n. 1095, p. 53
- Publication type:
- Article
3
R&D pipeline looking full.
- Published in:
- Australian Journal of Pharmacy, 2010, v. 91, n. 1077, p. 50
- Publication type:
- Article
4
New formulation Rebif.
- Published in:
- 2009
- Publication type:
- Product Review
5
Cefixime is first-line treatment for gonorrhoea in South Africa.
- Published in:
- Southern African Journal of Epidemiology & Infection, 2011, v. 26, n. 3, p. 103, doi. 10.1080/10158782.2011.11441435
- By:
- Publication type:
- Article
6
Movers & Shakers.
- Published in:
- Chemistry & Industry, 2013, v. 77, n. 12, p. 40, doi. 10.1002/cind.7712_12.x
- Publication type:
- Article
7
MS licensing agreement.
- Published in:
- Chemistry & Industry, 2008, n. 15, p. 5
- Publication type:
- Article
8
COMPANY SYMPOSIUM, MERCK-SERONO COMPANY SYMPOSIUM, Monday 4 July 2011 11:45 - 13:00, INVITED SESSION, SESSION 08: EARLY PREGNANCY, Monday 4 July 2011 11:45 - 12:45.
- Published in:
- Human Reproduction, 2011, v. 26, n. suppl_1, p. i16, doi. 10.1093/humrep/26.s1.8
- Publication type:
- Article
9
European Lead Factory opens for business.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 3, p. 173, doi. 10.1038/nrd3956
- By:
- Publication type:
- Article
10
Patent watch.
- Published in:
- Nature Reviews Drug Discovery, 2010, v. 9, n. 7, p. 508, doi. 10.1038/nrd3218
- By:
- Publication type:
- Article
11
Deal watch: Ablynx and Merck Serono collaborate on next-generation antibody products.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 11, p. 881, doi. 10.1038/nrd2754
- Publication type:
- Article
12
Newsmaker: Anaphore.
- Published in:
- Nature Biotechnology, 2010, v. 28, n. 11, p. 1143, doi. 10.1038/nbt1110-1143
- By:
- Publication type:
- Article
13
Corporate venture funds chase early-stage deals.
- Published in:
- Nature Biotechnology, 2009, v. 27, n. 5, p. 403, doi. 10.1038/nbt0509-403
- By:
- Publication type:
- Article
14
Movers & Shakers.
- Published in:
- Chemistry & Industry, 2014, v. 78, n. 6, p. 46, doi. 10.1002/cind.786_17.x
- Publication type:
- Article
15
Merck and Dr. Reddy's form biosimilars team.
- Published in:
- TCE: The Chemical Engineer, 2012, n. 853, p. 6
- Publication type:
- Article
16
Exhibitor Listing.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2012, p. 371, doi. 10.1111/ajco.12028_1
- Publication type:
- Article
17
Efalizumab: Results of a 3-Year Continuous Dosing Study for the Long-Term Control of Psoriasis.
- Published in:
- Dermatology Nursing, 2008, v. 20, n. 6, p. 487
- Publication type:
- Article
18
CAR-T field booms as next-generation platforms attract big players.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 6, p. 571, doi. 10.1038/nbt0615-571
- By:
- Publication type:
- Article
19
First-quarter biotech job picture.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 5, p. 465, doi. 10.1038/nbt.2581
- By:
- Publication type:
- Article
20
Merck Serono spinouts.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 10, p. 907, doi. 10.1038/nbt1012-907
- By:
- Publication type:
- Article
21
Swiss hope for phoenix from Merck Serono's ashes.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 7, p. 569, doi. 10.1038/nbt0712-569
- By:
- Publication type:
- Article
22
Realizing the potential of a multinational, multicultural organization: Lessons learned at Merck Serono.
- Published in:
- Global Business & Organizational Excellence, 2010, v. 30, n. 1, p. 7, doi. 10.1002/joe.20354
- By:
- Publication type:
- Article